Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 3, 2021

Primary Completion Date

January 10, 2022

Study Completion Date

January 10, 2022

Conditions
Covid19
Interventions
DRUG

Niclosamide

Niclosamide is a broad spectrum, host targeting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide solution is administered directly to the nasal cavity via a nasal spray.

DRUG

Placebo

The placebo formulation contains purified water, sodium chloride as common isotonizing agent and the FAO/WHO approved colorant FD\&C Red 40 to match the red-orange colour of the active solution. The solution is administered directly to the nasal cavity via a nasal spray.

Trial Locations (3)

Unknown

Klinische Forschung Berlin-Mitte GmbH, Berlin

Klinische Forschung Dresden GmbH, Dresden

Klinische Forschung Hamburg GmbH, Hamburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UNION therapeutics

INDUSTRY

NCT04932915 - Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19 | Biotech Hunter | Biotech Hunter